WO2026041965 - BICYCLIC IMIDAZO-THIADIAZOLE GRP119 AGONIST COMPOUNDS
National phase entry is expected:
Publication Number
WO/2026/041965
Publication Date
26.02.2026
International Application No.
PCT/IB2025/058218
International Filing Date
13.08.2025
Title **
[English]
BICYCLIC IMIDAZO-THIADIAZOLE GRP119 AGONIST COMPOUNDS
[French]
COMPOSÉS AGONISTES BICYCLIQUES D'IMIDAZO-THIADIAZOLE GRP119
Applicants **
MANKIND PHARMA LTD.
Inventors
RAI, Santosh Kumar
PATIL, Rakesh Ishwar
ALI, Sazid
KUMAR, Anil
Priority Data
202411063371
22.08.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1907 | |
| EPO | Filing, Examination, Granting | 8143 | |
| Japan | Filing, Examination, Granting | 2056 | |
| South Korea | Filing, Examination, Granting | 1798 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
19,244
Contact Us
Abstract[English]
This disclosure is directed to novel compounds that are useful in the treatment and/or prevention of metabolic disorders, including diabetes mellitus (Type I and Type II), and related disorders. This disclosure is also directed to methods for making these compounds, pharmaceutical compositions containing them, and therapeutic uses for such compounds.[French]
La présente divulgation concerne de nouveaux composés qui sont utiles dans le traitement et/ou la prévention de troubles métaboliques, y compris le diabète sucré (type I et type II), et des troubles apparentés. La présente divulgation concerne également des procédés de fabrication de ces composés, des compositions pharmaceutiques les contenant, et des utilisations thérapeutiques pour de tels composés.